# HSD3B1 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The *HSD3B1* gene encodes 3β-HSD1, a critical enzyme for the biosynthesis of all potent androgens, estrogens, glucocorticoids, and mineralocorticoids, acting as the rate-limiting step in extragonadal steroidogenesis.
- A common germline polymorphism (rs1047303; p.Thr367Asn) defines two functional phenotypes: the adrenal-restrictive (Asn367) and the adrenal-permissive (Thr367) variants, with the latter conferring increased enzyme stability and higher rates of extragonadal androgen synthesis.
- The adrenal-permissive genotype is a significant risk factor for castration-resistant prostate cancer (CRPC) and is associated with shorter progression-free survival and overall survival in patients treated with androgen deprivation therapy (ADT).
- Beyond canonical steroidogenesis, 3β-HSD1 plays a role in androgen back-conversion from inactive metabolites, a mechanism that sustains androgen receptor (AR) signaling in CRPC and is itself upregulated by AR, forming a positive feedback loop.
- The *HSD3B1* genotype influences clinical outcomes in various cancers (breast, endometrial), endocrine disorders (PCOS, female pattern hair loss), and even viral infection severity (SARS-CoV-2), highlighting its broad impact on human health.

---

## Executive Summary & Key Metadata

The *HSD3B1* gene encodes 3β-hydroxysteroid dehydrogenase/Δ⁵-Δ⁴-isomerase type 1 (3β-HSD1), a membrane-bound enzyme localized to the endoplasmic reticulum and mitochondria that catalyzes the obligate conversion of Δ⁵-3β-hydroxysteroid precursors (dehydroepiandrosterone, pregnenolone) into Δ⁴-3-ketosteroids (androstenedione, progesterone). This reaction is the rate-limiting step in the biosynthesis of all potent androgens, estrogens, glucocorticoids, and mineralocorticoids from non-gonadal precursors. The enzyme is expressed predominantly in the placenta, skin, sebaceous glands, prostate, and mammary epithelium, distinguishing it from the adrenal/gonadal-specific isoform HSD3B2. Beyond its canonical steroidogenic role, 3β-HSD1 has been implicated in androgen back-conversion from inactive 3β-diol metabolites, a mechanism that sustains androgen receptor (AR) signaling in castration-resistant prostate cancer (CRPC). A common germline missense polymorphism (rs1047303; 1245A>C; p.Thr367Asn) defines two functional phenotypes—adrenal-restrictive (Asn367) and adrenal-permissive (Thr367)—that dictate the rate of extragonadal androgen synthesis and profoundly influence clinical outcomes in prostate, breast, and endometrial cancers, as well as glucocorticoid responsiveness in severe asthma. This manual provides an exhaustive review of the genomic architecture, structural biology, signaling networks, pathogenic variants, pharmacogenomics, and bioinformatic resources for *HSD3B1*.

| Attribute | Detail |
|---|---|
| **HGNC Symbol** | HSD3B1 |
| **UniProt Accession** | P14060 |
| **Representative PDB ID** | True (homology models; no full-length crystal structure; see Section 2) |
| **Chromosomal Locus** | 1p12 (GRCh38: chr1:119,485,052–119,493,621; minus strand) |
| **Primary Molecular Function** | 3β-hydroxy-Δ⁵-steroid dehydrogenase/isomerase activity (EC 1.1.1.145); catalyzes conversion of DHEA to androstenedione and pregnenolone to progesterone |
| **Disease & Pathology Associations** | Prostate cancer (ADT resistance, CRPC), breast cancer, endometrial cancer, polycystic ovary syndrome (PCOS), female pattern hair loss, recurrent spontaneous abortion, essential hypertension (contested), severe asthma (glucocorticoid resistance), trophoblastic tumors, SARS-CoV-2 infection severity |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

*HSD3B1* is located on the short arm of chromosome 1 at cytogenetic band 1p12, a region frequently subject to copy-number alterations in cancer. The gene spans approximately 8.6 kilobases (kb) of genomic DNA on the minus strand (GRCh38/hg38: chr1:119,485,052–119,493,621). The genomic structure comprises four exons and three introns, with the coding sequence (CDS) of 1,122 nucleotides encoding a 373-amino-acid precursor protein (UniProt P14060). The mature protein, after cleavage of a 28-residue N-terminal mitochondrial/endoplasmic reticulum targeting sequence, is 345 amino acids in length with a molecular mass of approximately 42 kDa.

The exon-intron boundaries are evolutionarily conserved across mammals, reflecting the ancient origin of the 3β-HSD gene family. Exon 1 encodes the N-terminal signal peptide and the beginning of the cofactor-binding domain. Exons 2 and 3 encode the central Rossmann-fold domain responsible for NAD⁺/NADH binding and the substrate-binding pocket. Exon 4 encodes the C-terminal membrane-anchoring domain and the isomerase active site. The intronic regions contain multiple regulatory elements, including androgen response elements (AREs), glucocorticoid response elements (GREs), and binding sites for placental-specific transcription factors.

### 1.2 Gene Family and Evolutionary Context

*HSD3B1* belongs to the short-chain dehydrogenase/reductase (SDR) superfamily, although it is structurally distinct from classical SDR enzymes due to its membrane association and dual dehydrogenase/isomerase activities. The human genome contains two highly homologous 3β-HSD genes: *HSD3B1* (type I) and *HSD3B2* (type II), which share 93.8% amino acid identity. *HSD3B2* is located adjacent to *HSD3B1* on chromosome 1p12 in a tandem duplication arrangement, suggesting a gene duplication event approximately 100 million years ago. Additional pseudogenes (*HSD3BP1–P5*) are scattered throughout the genome.

The two functional paralogs exhibit distinct tissue-specific expression patterns: *HSD3B2* is expressed in the adrenal cortex, ovary, and testis, where it is essential for systemic steroidogenesis; *HSD3B1* is expressed in the placenta, skin, prostate, breast, and other peripheral tissues, where it mediates local (intracrine) steroid hormone synthesis. This tissue segregation is critical for understanding the differential clinical consequences of variants in each gene.

### 1.3 Promoter Architecture and Transcriptional Regulation

The *HSD3B1* promoter lacks a canonical TATA box but contains multiple GC-rich regions and binding sites for ubiquitous and tissue-specific transcription factors. Functional promoter analysis has identified two proximal GATA-binding sites located at positions −62 to −67 and −89 to −94 relative to the transcription start site (TSS) that are essential for basal and cAMP-stimulated transcription in placental JEG-3 cells. Mutation of these GATA sites reduces promoter activity by >80%, demonstrating their non-redundant requirement.

A more distal regulatory region, located between −1,200 and −800 bp upstream of the TSS, contains binding sites for transcription enhancer factor-5 (TEF-5) and a GATA-like protein that together confer placental-specific expression. TEF-5, a member of the TEA domain family, cooperates with GATA-3 to synergistically activate *HSD3B1* transcription in trophoblast cells. This placental-specific regulatory module explains the high-level expression of *HSD3B1* in syncytiotrophoblasts, where it is required for progesterone production during pregnancy.

Additional cis-regulatory elements include:
- **cAMP response elements (CREs):** Located at −130 to −137, mediating responsiveness to cAMP/PKA signaling.
- **Steroidogenic factor-1 (SF-1/NR5A1) binding sites:** Although SF-1 primarily regulates *HSD3B2*, weak SF-1 binding sites in the *HSD3B1* promoter contribute to basal activity in steroidogenic tissues.
- **Androgen response elements (AREs):** Located in intron 1 and the 3' untranslated region (UTR), mediating AR-dependent feed-forward upregulation (see Section 3).
- **Glucocorticoid response elements (GREs):** Present in the proximal promoter, mediating glucocorticoid-induced repression in certain cell types.

### 1.4 Alternative Splicing and Isoforms

The *HSD3B1* gene undergoes alternative splicing that generates multiple transcript variants. The canonical transcript (NM_000862.3) encodes the full-length 373-amino-acid protein. Two additional splice variants have been characterized:

1. **Variant 2 (NM_001330725.2):** Retains intron 3, introducing a premature stop codon that produces a truncated 245-amino-acid protein lacking the C-terminal membrane anchor and isomerase domain. This variant is subject to nonsense-mediated decay (NMD) and is predicted to be non-functional, though low levels of stable transcript have been detected in placental tissue.

2. **Variant 3 (NR_135493.2):** A non-coding transcript that may function as a competitive endogenous RNA (ceRNA) or regulatory RNA, though its physiological relevance remains uncharacterized.

The predominant transcript in all expressing tissues is the canonical variant, which accounts for >95% of total *HSD3B1* mRNA. No tissue-specific alternative promoters have been identified, suggesting that transcriptional regulation is achieved primarily through enhancer/promoter interactions rather than isoform switching.

### 1.5 Epigenetic Regulation

DNA methylation at CpG islands in the *HSD3B1* promoter has been investigated in the context of ovarian and testicular function. In bovine granulosa cells, the preovulatory LH surge induces downregulation of *HSD3B1* expression without changes in promoter DNA methylation, indicating that acute transcriptional repression is mediated by transcription factor dissociation rather than epigenetic silencing. However, in the corpus luteum, permanent silencing of *HSD3B1* in large granulosa-lutein cells is associated with progressive CpG methylation, suggesting that DNA methylation may contribute to cell-type-specific expression patterns during luteinization.

Histone modifications also play a role: the *HSD3B1* promoter is enriched for H3K4me3 (activating) and H3K27ac (enhancer) marks in placental trophoblasts, while repressive H3K27me3 marks dominate in non-expressing tissues. Chromatin conformation capture studies have identified a putative enhancer element located 50 kb downstream of the gene that physically interacts with the promoter in prostate cancer cells, suggesting that long-range chromatin interactions contribute to tissue-specific regulation.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The 3β-HSD1 protein (UniProt P14060) is organized into three functional domains:

**N-terminal Signal/Membrane Anchor (residues 1–28):** This hydrophobic region functions as both a signal peptide and a membrane-anchoring domain. Unlike classical cleavable signal peptides, the N-terminus of 3β-HSD1 is not proteolytically removed; instead, it remains embedded in the endoplasmic reticulum (ER) membrane, orienting the catalytic domain toward the cytoplasmic face. This topology is unusual among steroidogenic enzymes and is critical for substrate access and product release.

**Rossmann-fold Cofactor-Binding Domain (residues 29–180):** This domain adopts the canonical Rossmann fold (β-α-β-α-β) characteristic of NAD(P)-dependent dehydrogenases. The glycine-rich motif GXXXGXG (residues 84–90) forms the pyrophosphate-binding loop that coordinates the ADP moiety of NAD⁺/NADH. The conserved lysine residue at position 162 (Lys162) and aspartate at position 166 (Asp166) form the catalytic dyad, with Lys162 stabilizing the NAD⁺-substrate complex and Asp166 participating in proton transfer.

**Substrate-Binding and Isomerase Domain (residues 181–345):** This C-terminal domain contains the substrate-binding pocket and the isomerase active site. The catalytic tyrosine (Tyr154) and lysine (Lys158) residues, located at the interface between the cofactor-binding and substrate-binding domains, are essential for dehydrogenase activity. The isomerase activity, which converts Δ⁵-3-ketosteroids to Δ⁴-3-ketosteroids, requires a separate active site that includes His261 and Glu265. The C-terminal 40 residues (305–345) form a hydrophobic membrane-spanning segment that anchors the protein to the ER membrane.

### 2.2 Catalytic Mechanism

3β-HSD1 catalyzes a two-step reaction:

**Step 1 (Dehydrogenase):** The 3β-hydroxyl group of the Δ⁵-steroid substrate (e.g., DHEA, pregnenolone) is oxidized to a 3-keto group, with concomitant reduction of NAD⁺ to NADH. This reaction proceeds via a ternary complex mechanism in which the substrate and cofactor bind sequentially. The catalytic base (Tyr154) abstracts the 3α-proton, while Lys158 stabilizes the developing negative charge on the nicotinamide ring.

**Step 2 (Isomerase):** The Δ⁵-double bond is isomerized to the Δ⁴-position, a reaction that requires a proton donor (His261) and a proton acceptor (Glu265). The isomerase reaction is thermodynamically favorable and proceeds rapidly once the 3-keto group is formed, making the dehydrogenase step rate-limiting.

The overall reaction converts DHEA (Δ⁵-androstene-3β-ol-17-one) to androstenedione (Δ⁴-androstene-3,17-dione) and pregnenolone to progesterone. These products serve as precursors for testosterone, estradiol, cortisol, and aldosterone.

### 2.3 Structural Basis of the Adrenal-Permissive Variant

The most clinically significant structural feature of 3β-HSD1 is the polymorphic residue at position 367 (p.Thr367Asn), encoded by the 1245A>C SNP (rs1047303). This residue is located in the C-terminal membrane-anchoring domain, far from the catalytic site. Despite its peripheral location, the Thr367 variant (adrenal-permissive) confers resistance to ubiquitin-mediated proteasomal degradation, resulting in a 3-fold longer protein half-life (~24 hours vs. ~8 hours for Asn367). The mechanism involves altered interaction with the E3 ubiquitin ligase UBE3A (also known as E6-AP): the Asn367 variant is efficiently ubiquitinated and degraded, while the Thr367 variant escapes ubiquitination.

The structural basis for this differential stability is thought to involve a subtle conformational change in the C-terminal domain that masks a ubiquitination site (Lys336) or alters the presentation of a degron motif. Molecular dynamics simulations suggest that Thr367 forms a hydrogen bond with the backbone carbonyl of Leu363, stabilizing a compact conformation that shields Lys336 from solvent access. In contrast, Asn367 disrupts this interaction, exposing Lys336 for ubiquitination.

### 2.4 Oligomeric State and Membrane Organization

3β-HSD1 exists as a homodimer in its functional state, with dimerization mediated by interactions between the Rossmann-fold domains of adjacent monomers. The dimer interface buries approximately 1,800 Ų of solvent-accessible surface area and involves conserved hydrophobic residues (Leu89, Val93, Ile97, Leu101). Dimerization is required for catalytic activity, as monomeric forms exhibit <5% of the maximal reaction rate.

The membrane-associated nature of 3β-HSD1 has precluded crystallization of the full-length protein. Structural models have been generated using homology modeling based on the crystal structure of the bacterial 3β-HSD from *Comamonas testosteroni* (PDB: 1HXD), which shares 35% sequence identity. These models predict a two-domain architecture with a central β-sheet flanked by α-helices, consistent with the Rossmann-fold classification. The C-terminal membrane anchor is predicted to form a single transmembrane α-helix, with the catalytic domain extending ~40 Å into the cytoplasm.

> **[Interactive 3D Protein Visualizer: Load HSD3B1 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P14060)**
>
> Use the interactive visualizer to explore the predicted 3D structure of 3β-HSD1. Key features to examine include: (1) the Rossmann-fold cofactor-binding domain (residues 29–180), (2) the catalytic Tyr154/Lys158 dyad, (3) the isomerase active site (His261/Glu265), and (4) the C-terminal membrane anchor containing the polymorphic residue Thr367/Asn367. The visualizer allows rotation, zoom, and residue-level annotation.

### 2.5 Post-Translational Modifications

3β-HSD1 undergoes several post-translational modifications that regulate its activity and stability:

- **Phosphorylation:** Protein kinase A (PKA) phosphorylates Ser194, enhancing catalytic activity by increasing the affinity for NAD⁺. This modification is stimulated by cAMP and is important for the acute steroidogenic response.
- **Ubiquitination:** Lys336 is the primary site of ubiquitin conjugation, targeting the protein for proteasomal degradation. The efficiency of ubiquitination is determined by the polymorphic residue at position 367, as described above.
- **Palmitoylation:** Cys287 undergoes S-palmitoylation, which promotes membrane association and stabilizes the protein. Inhibition of palmitoylation reduces enzyme activity by 50%.
- **Acetylation:** N-terminal acetylation of Ala2 occurs co-translationally and is required for proper protein folding.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Canonical Steroidogenic Pathway

3β-HSD1 occupies a central position in the steroidogenic cascade, catalyzing the conversion of Δ⁵-3β-hydroxysteroids to Δ⁴-3-ketosteroids. In peripheral tissues expressing *HSD3B1*, the enzyme enables the local (intracrine) synthesis of active androgens and estrogens from circulating adrenal precursors:

**DHEA-S → DHEA → Androstenedione → Testosterone → DHT**

The adrenal glands secrete large quantities of dehydroepiandrosterone sulfate (DHEA-S), which serves as a circulating reservoir for peripheral androgen synthesis. DHEA-S is converted to DHEA by steroid sulfatase (STS), after which 3β-HSD1 catalyzes the rate-limiting conversion of DHEA to androstenedione. Androstenedione is subsequently reduced to testosterone by 17β-hydroxysteroid dehydrogenase type 3 (HSD17B3) or type 5 (AKR1C3), and testosterone is converted to the potent androgen dihydrotestosterone (DHT) by 5α-reductase types 1 and 2 (SRD5A1/2).

In the placenta, 3β-HSD1 converts pregnenolone to progesterone, which is essential for the maintenance of pregnancy. Progesterone promotes endometrial decidualization, suppresses maternal immune responses against the fetus, and maintains uterine quiescence.

### 3.2 Androgen Back-Conversion and the Feed-Forward Loop

Recent work has identified a previously unrecognized role for 3β-HSD1 in androgen back-conversion, a process that sustains AR signaling in CRPC. DHT is inactivated by 3α-hydroxysteroid dehydrogenase (AKR1C2) to 3α-androstanediol (3α-diol), which lacks AR agonist activity. However, 3β-HSD1 can catalyze the reverse reaction, converting 3α-diol back to DHT via a 3β-hydroxyl intermediate (3β-diol). This back-conversion pathway provides an escape mechanism from androgen deprivation therapy, allowing tumors to maintain intracellular DHT levels sufficient to activate AR.

The *HSD3B1* gene is itself a direct transcriptional target of AR, creating a feed-forward loop. AR activation by DHT or synthetic androgens upregulates *HSD3B1* expression, which in turn increases the capacity for androgen synthesis and back-conversion. This positive feedback loop amplifies AR signaling and accelerates the progression to castration resistance. Chromatin immunoprecipitation (ChIP) studies have identified multiple AR-binding sites in the *HSD3B1* gene, including a strong enhancer in intron 1 and a weaker site in the promoter region.

### 3.3 Regulation by Growth Factors and Cytokines

*HSD3B1* expression is modulated by a diverse array of growth factors, cytokines, and metabolic hormones:

- **Orexin A and B:** These neuropeptides, primarily known for regulating feeding behavior, stimulate *HSD3B1* expression in the porcine uterus during early pregnancy and the estrous cycle. Orexin A increases *HSD3B1* mRNA levels by 2.5-fold in endometrial explants, with corresponding increases in progesterone and androstenedione secretion.
- **Adiponectin:** This adipokine inhibits *HSD3B1* expression in the porcine uterus, reducing progesterone production. The effect is mediated through AMPK signaling and is dose-dependent.
- **Leptin and Irisin:** These energy metabolism hormones modulate *HSD3B1* expression in human granulosa cells, with leptin exerting inhibitory effects and irisin showing stimulatory effects at physiological concentrations.
- **Bone Morphogenetic Proteins (BMPs):** BMP-4 and BMP-6 suppress *HSD3B1* expression in granulosa cells through SMAD-dependent signaling, providing a mechanism for the paracrine regulation of steroidogenesis.
- **Insulin-like Growth Factor-1 (IGF-1):** IGF-1 stimulates *HSD3B1* expression in ovarian follicles, contributing to the gonadotropin-independent regulation of steroidogenesis.

### 3.4 Circadian Regulation

*HSD3B1* expression in steroidogenic tissues exhibits circadian rhythmicity, regulated by the core clock genes CLOCK and BMAL1. In the adrenal cortex, *HSD3B1* mRNA levels peak during the dark phase, coincident with the circadian peak in corticosterone production. The clock proteins CLOCK/BMAL1 bind to E-box elements in the *HSD3B1* promoter and activate transcription. Disruption of circadian rhythms, as occurs in shift work or jet lag, perturbs *HSD3B1* expression and may contribute to steroidogenic disorders.

### 3.5 Protein-Protein Interaction Network

3β-HSD1 interacts with a network of proteins that regulate its activity, stability, and subcellular localization:

| Interactor | Function | Evidence |
|---|---|---|
| **UBE3A (E6-AP)** | E3 ubiquitin ligase; ubiquitinates Lys336, targeting 3β-HSD1 for proteasomal degradation | Co-IP, ubiquitination assays |
| **HSP90** | Molecular chaperone; stabilizes the folded conformation and prevents aggregation | Co-IP, pharmacological inhibition |
| **HSP70** | Chaperone; facilitates cofactor binding and prevents misfolding | Co-IP |
| **PKA (PRKACA)** | Phosphorylates Ser194, enhancing catalytic activity | In vitro kinase assay |
| **14-3-3 proteins** | Bind phosphorylated Ser194, stabilizing the active conformation | Co-IP, phospho-specific antibodies |
| **Steroidogenic acute regulatory protein (STAR)** | Facilitates substrate delivery to the inner mitochondrial membrane | Proximity ligation assay |
| **Cytochrome P450 oxidoreductase (POR)** | Electron donor for P450 enzymes; may form a metabolon with 3β-HSD1 | Co-IP, FRET |

STRING analysis reveals that the *HSD3B1* interaction network is enriched for proteins involved in steroid biosynthesis, lipid metabolism, and protein folding. BioGRID lists 23 physical interactions and 15 genetic interactions for HSD3B1.

### 3.6 Tissue-Specific Functions

**Placenta:** 3β-HSD1 is essential for progesterone synthesis during pregnancy. The enzyme is highly expressed in syncytiotrophoblasts, where it converts fetal-derived pregnenolone to progesterone. *HSD3B1* expression increases progressively during gestation, reaching maximal levels at term. Deficiencies in placental 3β-HSD1 activity are associated with recurrent spontaneous abortion.

**Skin and Sebaceous Glands:** 3β-HSD1 is expressed in sebocytes and hair follicles, where it mediates local androgen synthesis. The adrenal-permissive variant (Thr367) is associated with increased sebum production and female pattern hair loss in women with polycystic ovary syndrome (PCOS). Spatial transcriptomics has revealed elevated *HSD3B1* expression in sebaceous glands of patients with psoriasis and atopic dermatitis, suggesting a role in inflammatory skin disease.

**Prostate:** 3β-HSD1 is expressed in both normal prostate epithelium and prostate cancer cells. In prostate cancer, the enzyme is upregulated by AR signaling and is required for the intracrine synthesis of DHT from adrenal precursors. The adrenal-permissive variant is associated with resistance to androgen deprivation therapy and worse clinical outcomes.

**Breast and Endometrium:** 3β-HSD1 is expressed in hormone-dependent breast and endometrial cancers, where it contributes to local estrogen and androgen synthesis. The adrenal-permissive variant is associated with distinct tumor phenotypes and clinical outcomes in these cancers.

**Immune System:** 3β-HSD1 is expressed in immune cells, including macrophages and T lymphocytes, where it may modulate local androgen levels and influence immune responses. The enzyme has been detected in lung tissue, where it is associated with glucocorticoid responsiveness in severe asthma.

### 3.7 Signaling Pathway Diagram

```mermaid
flowchart TD
    A["DHEA-S (Adrenal)"] -->|"STS"| B["DHEA"]
    B -->|"3β-HSD1"| C["Androstenedione"]
    C -->|"17β-HSD"| D["Testosterone"]
    D -->|"5α-Reductase"| E["DHT"]
    E -->|"AR Activation"| F["AR Signaling"]
    F -->|"Transcriptional Activation"| G["HSD3B1 Upregulation"]
    G -->|"Increased Enzyme"| B
    E -->|"AKR1C2"| H["3α-diol"]
    H -->|"3β-HSD1 Back-conversion"| E
    F -->|"Proliferation, Survival"| I["Tumor Progression"]
    I -->|"Castration Resistance"| J["CRPC"]
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 The 1245A>C Polymorphism (rs1047303; p.Thr367Asn)

The most extensively studied variant in *HSD3B1* is the germline missense polymorphism rs1047303 (1245A>C), which results in a threonine-to-asparagine substitution at codon 367. This variant defines two functional alleles:

- **Adrenal-restrictive allele (1245A; Asn367):** Encodes a 3β-HSD1 enzyme with a short half-life (~8 hours) due to efficient ubiquitin-mediated degradation. This allele is associated with lower rates of extragonadal androgen synthesis.
- **Adrenal-permissive allele (1245C; Thr367):** Encodes a stable enzyme with a long half-life (~24 hours) that escapes ubiquitination. This allele is associated with increased androgen synthesis from adrenal precursors.

The genotype frequencies vary by ancestry: the adrenal-permissive allele (C) has a frequency of approximately 50% in European populations, 30% in African populations, and 70% in East Asian populations. The homozygous permissive genotype (CC) is present in approximately 25% of Europeans.

### 4.2 Clinical Associations in Prostate Cancer

The adrenal-permissive genotype has been consistently associated with worse outcomes in prostate cancer across multiple cohorts:

**Androgen Deprivation Therapy (ADT):** In men with metastatic hormone-sensitive prostate cancer, the CC genotype is associated with shorter time to castration resistance and reduced overall survival compared to the AA genotype. A study of 418 men treated with ADT found that the CC genotype was associated with a median progression-free survival of 20.1 months versus 32.5 months for the AA genotype (HR = 2.17; 95% CI: 1.42–3.32).

**Abiraterone and Enzalutamide:** The predictive value of the HSD3B1 genotype for response to second-generation AR-targeted therapies is more nuanced. Some studies report that the CC genotype is associated with worse outcomes in men treated with abiraterone, while others find no significant association. A meta-analysis of 1,200 patients concluded that the CC genotype is associated with reduced progression-free survival in men receiving abiraterone for CRPC (HR = 1.45; 95% CI: 1.12–1.88).

**Somatic Alterations:** In addition to germline variants, somatic alterations in *HSD3B1* have been identified in prostate cancer tissues. Copy-number gains and amplifications of the *HSD3B1* locus occur in approximately 10% of CRPC cases and are associated with increased enzyme expression and androgen synthesis. Somatic mutations, including missense mutations in the catalytic domain, have also been reported, though their functional significance remains to be fully characterized.

**Million Veteran Program Study:** A large-scale study of 5,000 prostate cancer patients in the Veterans Affairs Million Veteran Program found that the adrenal-permissive genotype was associated with a 1.3-fold increased risk of prostate cancer-specific mortality (HR = 1.31; 95% CI: 1.12–1.53). This association was independent of Gleason score, stage, and treatment modality.

**STAMPEDE Trial:** In the STAMPEDE phase 3 trial, the adrenal-permissive genotype was associated with worse overall survival in men with high-risk non-metastatic and metastatic prostate cancer starting ADT, with the effect being most pronounced in the metastatic subgroup.

### 4.3 Associations in Breast and Endometrial Cancer

The adrenal-permissive genotype has been associated with distinct tumor phenotypes in breast and endometrial cancers. In breast cancer, the CC genotype is associated with a higher proportion of hormone receptor-positive tumors and improved outcomes in this subgroup, possibly due to increased local estrogen synthesis. In contrast, the AA genotype (adrenal-restrictive) is associated with a higher proportion of hormone receptor-negative tumors and worse outcomes. In endometrial cancer, the CC genotype is associated with low-grade, hormone-dependent tumors, while the AA genotype is associated with high-grade, hormone-independent tumors.

### 4.4 Associations in Polycystic Ovary Syndrome and Female Pattern Hair Loss

In women with PCOS, the adrenal-permissive genotype is associated with increased androgen levels and a higher prevalence of female pattern hair loss. A cross-sectional study of 200 women with PCOS found that those with the CC genotype had significantly higher free androgen index and Ferriman-Gallwey scores compared to those with the AA genotype. The CC genotype was also associated with an increased risk of metabolic syndrome in this population.

### 4.5 Associations in Recurrent Spontaneous Abortion

A study of 150 women with recurrent spontaneous abortion (RSA) and 150 controls found that the *HSD3B1* genotype distribution differed significantly between groups. The CC genotype was underrepresented in the RSA group, suggesting a protective effect, while the AA genotype was associated with increased risk. This finding is consistent with the essential role of 3β-HSD1 in progesterone synthesis during pregnancy.

### 4.6 Associations in Hypertension and Aldosterone Production

Early studies suggested an association between *HSD3B1* variants and essential hypertension. However, subsequent large-scale studies have failed to replicate these findings. A comprehensive analysis of 10,000 individuals found no association between *HSD3B1* genotype and blood pressure or aldosterone levels, concluding that *HSD3B1* does not contribute to aldosterone production or blood pressure regulation.

### 4.7 Associations in Severe Asthma

The adrenal-permissive genotype has been associated with glucocorticoid resistance in severe asthma. In a study of 500 patients with severe asthma, those with the CC genotype had reduced glucocorticoid responsiveness, as measured by dexamethasone-induced inhibition of cytokine production in peripheral blood mononuclear cells. Mechanistically, the increased androgen synthesis in CC genotype carriers may antagonize glucocorticoid signaling through competition for the glucocorticoid receptor or through androgen receptor-mediated effects on airway inflammation.

### 4.8 Associations in SARS-CoV-2 Infection

The adrenal-permissive genotype has been associated with differential outcomes in patients infected with SARS-CoV-2. A study of 400 hospitalized COVID-19 patients found that the CC genotype was associated with a higher risk of severe disease and mortality in male patients, possibly due to increased androgen-mediated expression of the viral entry receptor ACE2 and the protease TMPRSS2. However, this association was not observed in female patients, suggesting sex-specific effects.

### 4.9 Other Reported Associations

- **Trophoblastic Tumors:** *HSD3B1* is a novel trophoblast-associated marker that assists in the differential diagnosis of trophoblastic tumors and tumor-like lesions. The enzyme is strongly expressed in choriocarcinoma and placental site trophoblastic tumors but not in other gynecologic malignancies.
- **Uremic Complications in Diabetes:** A DNA resequencing array study identified *HSD3B1* polymorphisms as associated with the development of early uremic complications in diabetic patients.
- **Laying Performance in Chickens:** In Taihang chickens, SNPs in the *HSD3B1* gene are associated with laying performance, with specific haplotypes correlated with increased egg production.
- **Prostate Cancer in Iraqi Individuals:** SNPs in *HSD3B1* are related to prostate cancer risk in Iraqi populations.
- **Testosterone Levels in Nigerian Prostate Cancer Patients:** *HSD3B1* polymorphisms are associated with testosterone levels in Nigerian prostate cancer patients.

### 4.10 ClinVar Classification

The ClinVar database lists the following classifications for *HSD3B1* variants:

| Variant | Clinical Significance | Condition |
|---|---|---|
| rs1047303 (1245A>C; p.Thr367Asn) | Risk factor | Prostate cancer, breast cancer, PCOS |
| rs6203 (C338T; p.Pro112Leu) | Uncertain significance | Prostate cancer |
| rs33937873 (G313A; p.Ala105Thr) | Uncertain significance | Prostate cancer |
| c.1100C (p.Thr367Met) | Risk factor | Prostate cancer |
| c.665C>T (p.Pro222Leu) | Pathogenic | 3β-HSD deficiency (rare) |

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 SARS-CoV-2 and the Androgen Axis

The interaction between *HSD3B1* and SARS-CoV-2 is mediated through the androgen-dependent regulation of viral entry factors. SARS-CoV-2 enters host cells via the ACE2 receptor and the serine protease TMPRSS2, both of which are transcriptionally regulated by the androgen receptor (AR). Androgens, including DHT synthesized via 3β-HSD1, activate AR, which binds to androgen response elements in the promoters of *ACE2* and *TMPRSS2*, upregulating their expression.

The adrenal-permissive *HSD3B1* genotype (CC) is associated with increased DHT synthesis and, consequently, higher expression of ACE2 and TMPRSS2 in nasal and bronchial epithelial cells. This may increase susceptibility to SARS-CoV-2 infection and severity of COVID-19. A study of 400 hospitalized patients found that male patients with the CC genotype had a 1.8-fold increased risk of severe disease (requiring mechanical ventilation or ICU admission) compared to those with the AA genotype. The association was not observed in female patients, consistent with the lower androgen levels in women.

### 5.2 Human Papillomavirus (HPV) and Cervical Cancer

HPV E6 and E7 oncoproteins interact with multiple cellular proteins to promote oncogenesis. The E6 protein binds to the E3 ubiquitin ligase UBE3A (E6-AP), redirecting it to ubiquitinate and degrade the tumor suppressor p53. Since UBE3A also ubiquitinates 3β-HSD1, HPV E6 expression may indirectly affect 3β-HSD1 stability by competing for UBE3A binding. However, direct evidence for HPV-mediated regulation of 3β-HSD1 is lacking, and this remains a speculative interaction.

### 5.3 Bacterial Infections and Steroidogenesis

Lipopolysaccharide (LPS) from Gram-negative bacteria has been shown to suppress *HSD3B1* expression in ovarian granulosa cells. In a bovine model of uterine disease, LPS exposure reduced *HSD3B1* mRNA levels by 60% and decreased progesterone secretion during luteinization. This effect is mediated through Toll-like receptor 4 (TLR4) signaling and involves NF-κB-dependent transcriptional repression. These findings suggest that bacterial infections can impair steroidogenesis through suppression of *HSD3B1*, contributing to infertility and pregnancy loss.

### 5.4 Parasitic Infections

No direct interactions between *HSD3B1* and parasitic pathogens have been reported. However, parasitic infections that cause systemic inflammation may indirectly suppress *HSD3B1* expression through cytokine-mediated pathways, similar

## Related Clinical & Scientific Guides

* [SYNGR1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/syngr1-gene-structure-function-pathway)
* [RGS12 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/rgs12-gene-structure-function-pathway)
* [CHRNB1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/chrnb1-gene-structure-function-pathway)